• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替勃龙对乳腺癌患者接受5年他莫昔芬治疗后的绝经后女性的临床疗效。

Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.

作者信息

Dimitrakakis C, Keramopoulos D, Vourli G, Gaki V, Bredakis N, Keramopoulos A

机构信息

Breast Center, Iaso Women's Health Hospital, Marousi, Athens, Greece.

出版信息

Climacteric. 2005 Dec;8(4):342-51. doi: 10.1080/13697130500345216.

DOI:10.1080/13697130500345216
PMID:16390769
Abstract

OBJECTIVES

This observational, prospective, open, non-randomized study was designed to assess the safety and efficacy of tibolone for the treatment of climacteric symptoms in women with a history of breast cancer.

METHODS

A total of 156 women who had been treated for breast cancer and had received tamoxifen for 5 years participated in the study. One month after stopping tamoxifen, 52 women started taking tibolone while the rest served as untreated controls (n = 104). They were followed up (mean duration 61 months) for climacteric symptoms, cancer recurrence rate, breast density, endometrial thickness and adverse events.

RESULTS

There was no difference in cancer recurrence rate between the two groups. Breast density was not affected. Tibolone treatment alleviated climacteric symptoms and positively affected sexual problems. Endometrial thickness was not adversely affected by treatment and there was a low incidence of adverse events.

CONCLUSIONS

Tibolone was effective in the treatment of climacteric symptoms and well tolerated in a group of 52 women with a history of breast cancer. The cancer recurrence rate in the tibolone group was comparable to that of untreated controls. It should be noted that the limitations of the study design and the small number of events preclude any definitive conclusions about the effects of tibolone on breast cancer recurrence in general clinical practice. There were no breast-related adverse effects, and overall safety and tolerance were similar to those of the general population of postmenopausal women treated with tibolone.

摘要

目的

本观察性、前瞻性、开放性、非随机研究旨在评估替勃龙治疗有乳腺癌病史女性更年期症状的安全性和有效性。

方法

共有156名接受过乳腺癌治疗且已服用他莫昔芬5年的女性参与了该研究。在停止服用他莫昔芬1个月后,52名女性开始服用替勃龙,其余女性作为未治疗对照组(n = 104)。对她们进行随访(平均持续时间61个月),观察更年期症状、癌症复发率、乳腺密度、子宫内膜厚度及不良事件。

结果

两组的癌症复发率无差异。乳腺密度未受影响。替勃龙治疗缓解了更年期症状,并对性问题有积极影响。治疗未对子宫内膜厚度产生不利影响,不良事件发生率较低。

结论

替勃龙对52名有乳腺癌病史的女性治疗更年期症状有效且耐受性良好。替勃龙组的癌症复发率与未治疗对照组相当。应当指出,研究设计的局限性和事件数量较少,使得在一般临床实践中无法就替勃龙对乳腺癌复发的影响得出任何确定性结论。未出现与乳腺相关的不良反应,总体安全性和耐受性与接受替勃龙治疗的绝经后女性总体人群相似。

相似文献

1
Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.替勃龙对乳腺癌患者接受5年他莫昔芬治疗后的绝经后女性的临床疗效。
Climacteric. 2005 Dec;8(4):342-51. doi: 10.1080/13697130500345216.
2
Effects of tibolone on the breast of postmenopausal women.替勃龙对绝经后女性乳房的影响。
Taiwan J Obstet Gynecol. 2007 Jun;46(2):121-6. doi: 10.1016/S1028-4559(07)60005-9.
3
Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.口服替勃龙1.25毫克/天或2.5毫克/天与安慰剂相比对绝经后女性的疗效和安全性
Eur Rev Med Pharmacol Sci. 2003 Sep-Oct;7(5):117-25.
4
Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.比较常规激素替代疗法和替勃龙对绝经后妇女绝经期症状和性功能障碍的影响。
Climacteric. 2010 Apr;13(2):147-56. doi: 10.1080/13697130903009195.
5
Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.替勃龙与子宫内膜息肉风险:一项与激素疗法对比的前瞻性研究
Menopause. 2003 Nov-Dec;10(6):534-7. doi: 10.1097/01.GME.0000064815.74043.32.
6
A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.一项关于激素疗法、替勃龙和雷洛昔芬对阴道出血及子宫内膜厚度影响的5年研究。
Maturitas. 2006 Mar 20;53(4):413-23. doi: 10.1016/j.maturitas.2005.07.003. Epub 2005 Sep 2.
7
[Effects of hormonal replacement therapy on breast density in postmenopausal women].[激素替代疗法对绝经后女性乳腺密度的影响]
Minerva Ginecol. 2004 Apr;56(2):125-30.
8
[Is the clinical profile of women treated with tibolone similar to that of women receiving a classical estrogen-progestogen therapy? Data from a nationwide survey in France].[替勃龙治疗的女性的临床特征与接受传统雌激素 - 孕激素疗法的女性相似吗?来自法国全国性调查的数据]
Gynecol Obstet Fertil. 2006 Mar;34(3):224-32. doi: 10.1016/j.gyobfe.2006.01.027. Epub 2006 Mar 2.
9
Short-term and long-term effects of tibolone in postmenopausal women.替勃龙对绝经后女性的短期和长期影响。
Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD008536. doi: 10.1002/14651858.CD008536.pub3.
10
Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.替勃龙对乳腺癌患者绝经期症状和生活质量的影响——来自 LIBERATE 试验的数据。
Maturitas. 2011 Dec;70(4):365-72. doi: 10.1016/j.maturitas.2011.09.003. Epub 2011 Oct 26.

引用本文的文献

1
Menopausal Hormone Therapy in Breast Cancer Survivors.乳腺癌幸存者的绝经激素治疗
Cancers (Basel). 2024 Sep 26;16(19):3267. doi: 10.3390/cancers16193267.
2
Risk factors, pathophysiology, and treatment of hot flashes in cancer.癌症相关热潮红的风险因素、病理生理学和治疗。
CA Cancer J Clin. 2013 May;63(3):167-92. doi: 10.3322/caac.21171. Epub 2013 Jan 25.